←
Joshua Meeks2,441 posts
Joshua Meeks avatar✓

Joshua Meeks ✓

@JoshMeeks

Urologic Oncologist and Scientist at Northwestern University K-index:3.7

◷ Joined July 2009▧ 343 Photos and videos
Uromigos avatar
⟳ Joshua Meeks retweeted
Uromigos@Uromigos·Nov 14

There are now 2 (EVP and EVD) FDA approved regimens available in MIBC . The panel @tompowles1 @shilpaonc @MichvdHeijden @kalasri3 @DrRosenbergMSK @MattGalsky @PGrivasMDPhD @JoshMeeks Anna Wilkins Rough conclusion from #UromigosLive : 👉Both these regimens are better than any other option. Both trials are robust and very positive. Both are a reasonable approach. EV/D 1st ask questions later @MichvdHeijden 👉EVP gives you the flexibility to give the adjuvant period if you want, and some may need it, especially the higher TNM stage. Biomarkers don’t help @DrRosenbergMSK 👉It’s not clear who needs the adjuvant period, but 9 cycles is not for everyone. Most in the trials didn’t get to 9 cycles @shilpaonc 👉EVD does not have the adjuvant ADC period and will be attractive for some patients and doctors. 👉Stick to the protocol and don’t let ctDNA or pCR or TMT take you off course too much @MosheOrnsteinMD 👉Bladder sparing are already attractive @kalasri3 but let’s wait for the trial results @MattGalsky 👉’Pick one and use it well’ maybe more imporant than the deliberation over the optimal regimen as it’s true that only half the pateint finish the IO therapy. @tompowles1 @uromigos encourage the panel, participants or wider audience to comment or correct @OncoAlert x.com/i/broadcasts/2XybkVKqb…

Uromigos avatar
⟳ Joshua Meeks retweeted
Uromigos@Uromigos·Nov 14

ctDNA is FDA approved and widely used in MIBC but when should we use it?  @tompowles1 @shilpaonc @MichvdHeijden @kalasri3 @DrRosenbergMSK @MattGalsky @PGrivasMDPhD @JoshMeeks Anna Wilkins Rough summary from #UromigosLive : 👉ctDNA is strongly prognostic. Persistent ctDNA positivity despite treatment is very bad. 👉While adjuvant atezo in ctDNA+ves is attractive (IM011) most are now getting upfront EVP/D so IM011 is not so relevant. 👉ctDNA results from IM011 tell us when to start adjuvant atezo not when to stop neoadjuvant EVP/D. Some will use ctDNA to help determine EV duration, others don’t agree. Trials like MODERN may address this. 👉almost everyone would not stop IO within a year. 👉ctDNA and utDNA will help determine treatment in bladder sparing approaches (EV209,309, Trofuse55). Longer periods of ADC maybe needed here. #UromigosLive @OncoAlert

Post attachment
Uromigos avatar
⟳ Joshua Meeks retweeted
Uromigos@Uromigos·Nov 14

There are now 2 (EVP and EVD) FDA approved regimens available in MIBC . The panel @tompowles1 @shilpaonc @MichvdHeijden @kalasri3 @DrRosenbergMSK @MattGalsky @PGrivasMDPhD @JoshMeeks Anna Wilkins Rough conclusion from #UromigosLive : 👉Both these regimens are better than any other option. Both trials are robust and very positive. Both are a reasonable approach. EV/D 1st ask questions later @MichvdHeijden 👉EVP gives you the flexibility to give the adjuvant period if you want, and some may need it, especially the higher TNM stage. Biomarkers don’t help @DrRosenbergMSK 👉It’s not clear who needs the adjuvant period, but 9 cycles is not for everyone. Most in the trials didn’t get to 9 cycles @shilpaonc 👉EVD does not have the adjuvant ADC period and will be attractive for some patients and doctors. 👉Stick to the protocol and don’t let ctDNA or pCR or TMT take you off course too much @MosheOrnsteinMD 👉Bladder sparing are already attractive @kalasri3 but let’s wait for the trial results @MattGalsky 👉’Pick one and use it well’ maybe more imporant than the deliberation over the optimal regimen as it’s true that only half the pateint finish the IO therapy. @tompowles1

Post attachment
Ashish M. Kamat, MD, MBBS avatar
⟳ Joshua Meeks retweeted
Ashish M. Kamat, MD, MBBS@UroDocAsh·Oct 28

We need thoughtful, forward-thinking surgeons like @wandering_gu at the ASCO leadership table, bringing the surgical perspective to how we advance multidisciplinary cancer care. Todd Morgan is an exceptional surgeon and researcher, and someone I have tremendous respect for. Voting is now open asco.org/about-asco/asco-ove…

Post attachment
Journal of Clinical Investigation avatar
⟳ Joshua Meeks retweeted
Journal of Clinical Investigation@jclinicalinvest·Jul 1

BCG has been used as an immunotherapy for bladder cancer for over 50 years, yet its immunoregulatory mechanisms and causes of resistance remain unclear. doi.org/10.1172/JCI200442 Here, Joshua James Meeks @JoshMeeks, Weiguo Cui @Cui_Lab & team @NUFeinbergMed analyzed the tumor microenvironment in patients with bladder cancer, identifying dynamic regulation of myeloid-T cell interactions as a critical for outcomes of BCG. The figure shows the study design and patient cohort for immune profiling of the bladder cancer tumor microenvironment during BCG therapy. #BladderCancer #BCGtherapy

Post attachment
NEJM avatar
⟳ Joshua Meeks retweeted
NEJM@NEJM·May 31

Presented at #ASCO26: In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00 Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW @ASCO

Post attachment
Uromigos avatar
⟳ Joshua Meeks retweeted
Uromigos@Uromigos·May 28

We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 open.spotify.com/episode/2jM…

Joshua Meeks avatar
Joshua Meeks@JoshMeeks·May 17

GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.

Post attachmentPost attachment